210
Participants
Start Date
May 2, 2023
Primary Completion Date
July 30, 2026
Study Completion Date
July 30, 2026
RO7656594
RO7656594 will be administered orally at specified dose on specified days.
RECRUITING
St Vincent's Hospital Sydney, Darlinghurst
RECRUITING
Macquarie University Hospital, New South Wales
RECRUITING
Austin Hospital, Heidelberg
RECRUITING
Monash Health Monash Medical Centre, Clayton
RECRUITING
Institut Paoli Calmettes, Marseille
RECRUITING
Clinica Universidad de Navarra-Madrid, Madrid
RECRUITING
Hospital Clinico San Carlos, Madrid
RECRUITING
Clinica Universidad de Navarra, Pamplona
RECRUITING
Sarah Cannon Research Institute @ Florida Cancer, Orlando
RECRUITING
Tennessee Oncology - Nashville, Nashville
RECRUITING
University of Illinois Hospital & Health Sciences System, Chicago
RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
HonorHealth, Scottsdale
RECRUITING
Yale Cancer Center, New Haven
RECRUITING
British Columbia Cancer Agency, Vancouver
RECRUITING
Princess Margaret Hospital, Toronto
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital Yonsei University Health System - PPDS, Seoul
RECRUITING
Asan Medical Center - PPDS, Seoul
RECRUITING
Samsung Medical Center - PPDS, Seoul
RECRUITING
Hospital Universitario Vall d'Hebron - PPDS, Barcelona
RECRUITING
Cambridge Clinical Research Centre, Cambridge
RECRUITING
Leicester Royal Infirmary, Leicester
RECRUITING
The Christie, Manchester
RECRUITING
Royal Marsden Hospital - Surrey, Sutton
Lead Sponsor
Genentech, Inc.
INDUSTRY